Main Menu

This groundbreaking technology entails the utilization of genetically modified mice, specifically engineered to enable the non-destructive detection and isolation of cells actively transcribing the IL-4 and IL-13 genes. By expressing Amcyan and DsRed-DR fluorescent proteins under the control of these gene loci, researchers gain a powerful tool for studying cytokine gene expression without the need for cell death, offering significant advantages over traditional intracellular staining methods.

This technology includes Streptococcus pneumoniae isolates collected through CDC’s Global Strain Bank project with particular serotypes. They were collected as part of routine clinical and surveillance activities and have a wide variety of uses including research, diagnostic, and the development of therapeutics.

This technology includes Klebsiella pneumoniae isolate to be used for research studies and diagnostic tests to detect antimicrobial resistance.

This technology includes an Escherichia coli isolate to be used in for research purposes and the development of diagnostics. The isolate is unique because it has the mcr-1 gene.

This technology includes an isolate of the yeast species Candida auris to be used in the development of diagnostic tools or anti-fungal for therapeutic use.

This technology includes natural Yellow Fever Virus, Zika Virus, and Powassan Virus isolates for various uses in research and development of diagnostics and immunizations.

The Ligand Epitope Antigen Presentation System (LEAPS) represents a breakthrough in immunotherapeutic technology developed by CEL-SCI Corporation. This technology employs a novel approach to boost the immune system's response to influenza, aiming to treat, manage, or even prevent the illness. By combining LEAPS with a specific peptide from the influenza virus, and administering it intravenously in mice, there's a marked improvement in the immune system's ability to fight off the virus.

Summary:

 The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a method of identifying and selectively expanding neoantigen-specific T cells.

The discovery outlined in the Employee Discovery and Invention Report represents a significant advancement in veterinary vaccine technology, specifically targeting the bovine respiratory syncytial virus (bRSV). This innovation involves a "DS2" version of the bRSV F vaccine, which has been engineered to enhance immunogenicity through a prefusion-stabilized form of the F protein, absent of the fusion peptide and reinforced by cavity-filling mutations and inter-protomer disulfides.